Abstract: An aqueous preparation comprising of 0.1 to 0.3% (W/V) of a pyrido[1,2-a]pyrimidine compound represented by the following formula: ##STR1## wherein R represents an n-propyl or allyl group, A represents a tetrazolyl or carboxyl group, and n represents an integer of 0 to 2, 0.5 to 2.0% (W/V) of a polyoxyethylene sorbitan fatty acid ester, 0.5 to 2.0% (W/V) of polyethylene glycol and 1.0 to 3.5% (W/V) of disodium hydrogenphosphate.

Abstract: The invention relates to the use of dextran sulphate, optionally in combination with anti-androgen agents, for the treatment of the human prostatic carcinoma. Inhibition of the growth of both androgen-dependent and androgen-independent carcinoma cells is achieved according to the invention. The invention therefore leads to a significant improvement in the possible therapies for human prostatic carcinoma.

Abstract: A method and composition for inhibition of abnormal postnatal ocular growth are disclosed. The composition comprises vasoactive intestinal peptide (VIP), PHI or a analogue of these peptides. The method for inhibition of abnormal postnatal ocular growth comprises administering to the eye of an animal effective amount of VIP, PHI or analogue of these peptides.

Abstract: Pro-liposome compositions comprise membrane lipids such as lecithin or distearyl dimethylammonium chloride, water-miscible solvents such as ethanol, optionally a minor proportion of water, and optionally fatty acid esters and drugs. In addition to excess water they spontaneously form dispersions of liposomes having high void volumes and high drug entrapment ratios. Aerosol compositions are presented in a volatile liquid propellant. On being sprayed they form an aerosol of droplets which, on contact with aqueous media, spontaneously form liposome dispersions.

Abstract: A new controlled release vehicle which acts by breakdown of the entrapping material upon hydration has been developed. The preferred release vehicle is made of a carboxylated cellulose, e.g., carboxymethylcellulose, which is treated with a cross-linking agent such as aluminum ions and, preferably, a hydrophobicity agent such as acetic acid. The vehicle is broken down by a release agent, e.g., cellulase, which may be coated on the vehicle together with a coating agent, e.g., hydroxypropylcellulose. The vehicle is dried, entrapping the molecular to be entrapped, e.g., an enzyme, and hydration activates the cellulase which breaks down the carboxymethylcellulose, releasing the entrapped molecular.

Abstract: The invention relates to hemoglobin-containing liposomes in which an aqueous solution of hemoglobin is incorporated comprising liposome membrane mainly composed of hydrogenated phospholipids of hydrogenation ratio of 50% or more and an aqueous hemoglobin solution containing hemoglobin in a concentration of 30-60% (w/v). The method of preparation involves dissolving liposome membrane-forming lipids in an organic solvent, removing the solvent from said solution, adding an aqueous hemoglobin solution to the residue, subjecting the mixture to a shaking or an ultrasonication to give a uniform suspension, applying gas pressure to said suspension to allow said gas to permeate throughout said suspension and then subjecting said suspension to high pressure-delivery through fine openings. It is preferred that viscosity of the aqueous solution is 10.sup.2 -3,000 cP (20.degree. C.) and the inert gas pressure is 80-130 kg/cm.sup.2.

Abstract: Osmotically derived liposomal vesicles loaded with an active agent are disclosed. Liposomes, including an entrapped osmotic agent, are contacted one or more times with a washing solution which is hypotonic to the entrapped osmotic agent and which contains active agent. The entrapped osmotic agent in the liposome and the active agent in the washing solution are each present in concentrations causing the liposomes to swell, rupture under osmotic pressure, spill osmotic agent into the washing solution and re-form to encapsulate active agent.

Abstract: A non-conventional lipid particle formulation for the sustained release and delivery of steroids into deep lung is disclosed. The formulation provides prolonged release of the drug, improved therapeutic ratio, lower toxicity, reduced systemic side effects, and stability for several months. The formulation is in particular suitable for treatment of interstitial lung diseases.

Abstract: There are described novel dispersible tablets of dihydroergotoxine or of acid addition salts thereof, containing 0.1 to 4% by weight of dihydroergotoxine or its acid addition salts, 4 to 60% by weight of one or more disintegrating agents, 0.8 to 10% by weight of an organic acid and, optionally, 0.2 to 2% by weight of an antioxidizing agent together with other common adjuvants. The process for the manufacture of dispersible tablets of dihydroergotoxine and of acid addition salts thereof is carried out on the basis of known methods by granulating the ingredients and by compressing the granulate to tablets. Dispersible tablets disintegrate within less than 1 minute when brought in contact with water at room temperature to yield a fine dispersion, which facilitates the oral application. Therefore such tablets are particularly suitable for the aged. Dispersible tablets containing dihydroergotoxine or acid addition salts thereof excell by their improved rate of dissolution and good bioavailability.

Abstract: A pharmaceutical composition is described which comprises a pharmaceutically acceptable carrier and a compound of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof wherein X is CH.sub.2 or S, in an amount sufficient to stimulate selectively histamine H.sub.3 -receptors.

Abstract: The present invention describes a composition consisting of liposomes covalently or non-covalently coupled to the glycoprotein streptavidin. The streptavidin may additionally be coupled to biotinated proteins such as Immunoglobulin G or monoclonal antibodies. The liposomes of the invention may have a transmembrane potential across their membranes, and may be dehydrated. In addition, the composition may contain ionizable bioactive agents such as antineoplastic agents, and may be used in diagnostic assays.This is a divisional application of copending application Ser. No. 941,913, filed Dec. 15, 1986, which is now U.S. Pat. No. 4,885,172, which is a continuation-in-part of copending application Ser. No. 811,037, which in turn is a continuation-in-part of copending application Ser. No. 749,161, filed June 26, 1985, both now abandoned and copending application Ser. No. 759,419, filed July 26, 1985 now U.S. Pat. No. 4,870,635.

Abstract: The reaction product of H.sub.2 O.sub.2 and metallic titanium, a titanium peroxy radical gel, exhibits oxidizing and anti-inflammatory effects and is used, for instance, as a biocompatible oxidant, an anti-inflammatory agent or in vitro coating of an implant body. The gel-like product is produced by treating metallic titanium with H.sub.2 O.sub.2.

Abstract: The invention relates to a composition for the prevention and medical treatment of parondonthopathy. The composition contains the aqueous or aqueous with other solvent extract of greater celandine (Chelidonii herba), peppermint leaf(Menthae pip. fol.), marigold (Celendulae flos), thyme (Thymi herba), millfoil (Millefolii herba), optionally chamomile (Chamomillae flos), melilot leaf (Melissae fol.), and clove (Cariophylli flos) or arnica (Arnicae flos).

Abstract: A process for preparing a co-poly(amide/peptide) by reacting polymeric or oligomeric polypeptides and polymeric or oligomeric polyamides in the presence of an effective amount of one or more aryl phosphoryl azide compounds.

Abstract: A biodegradable hydrogel matrix is provided, useful for the controlled release of pharmacologically active agents. The matrix is formed by cross-linking a proteinaceous component and a polysaccharide or mucopolysaccharide, and then loading a selected drug therein. By varying temperature, ionic strength, and the composition of the hydrogel matrix, one can control degradation kinetics, the degree of uptake of a particular pharmacologically active agent, and the overall times release profile.

Abstract: A composite, porous membrane is formed from a porous polymer membrane having desired bulk properties on which is directly coated a cell attachment and/or growth promoting composition and a cross-linked polymer having desired surface properties. The composite membrane retains the porosity of the porous polymeric membrane. In one embodiment, when the substrate is polytetrafluoroethylene the composite is microscopically transparent.

Abstract: Transdermal drug delivery systems comprise a backing or enclosure having a matrix layer which incorporates a drug and a percutaneous enhancer for the drug. The percutaneous enhancer and/or drug will be contained within polymeric particles dispersed through the matrix layer, where the polymeric particles define pore networks which are sized to release the enhancer and/or drug into the matrix layer at rate(s) selected to provide for a desired rate of drug penetration. By isolating the enhancer within the polymeric particles, adverse interactions between the enhancer and the matrix layer and/or the drug can be minimized. Moreover, the release rate of the enhancer into the matrix layer can be carefully controlled, which in turn controls the penetration rate of the drug into the treated host.

Abstract: The invention relates to a platinum-(IV)-diamine complex of the formula: ##STR1## to a method for the preparation of said compound and to a preparation with an antitumor action containing said compound. Further said preparations with an antitumor action containing said compounds are disclosed.

Abstract: A novel glycoside, 4.sup.G -alpha-D-glucopyranosyl rutin, is formed by a saccharide-transferring enzyme and glucoamylase in a solution which contains rutin together with glucoamylase. The 4.sup.G -alpha-D-glucopyranosyl rutin formed in such a solution is purified with a synthetic macroreticular resin, and crystallization in an organic solvent yields a complex crystal with the organic solvent. 4.sup.G -Alpha-D-glucopyranosyl rutin exhibits the same molecular absorption coefficient as intact rutin, and is readily water-soluble, substantially tasteless and odorless, and readily hydrolyzable in vivo to exhibit physiological activities inherent to rutin. These render 4.sup.G -alpha-D-glucopyranosyl rutin very useful as a highly-safe, natural yellow coloring agent, antioxidant, stabilizer, quality-improving agent, preventive, remedy, uv-absorbent and deterioration-preventing agent in foods, beverages, tobaccos, cigarets, feeds, pet foods, pharmaceuticals, cosmetics and plastics.

Abstract: The material according to the invention comprises a mesh (3) confining a hydratable gel (4) in a thin film is its holes. The gel is used for its properties of absorption of the water provided by a moistening of the surface of the skin; it is rehydrated at least partially and with the mesh resuming its natural flexibility molds to the irregularities of the body; then it dries under the influence of the normal skin temperature, the dry form being resumed while it continues to adhere to the skin. Because the gel is confined in its mesh, it can be pulled off all in one piece, so that the gel thereby performs a skin sloughing treatment.